MiRNA-based Therapeutic Strategy in Lung Cancer

Author(s): Guang Li, Jing Fang, Ying Wang, Hu Wang*, Cheng-Cao Sun*.

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 39 , 2017

Become EABM
Become Reviewer

Abstract:

Lung cancer is one of the most common malignant tumors in the world. Although advanced therapies have been applied for the treatment of lung cancer, the prolongation of overall survival is limited due to treatment resistance. MicroRNAs (miRNAs) are a class of small non-coding, endogenous RNA molecules (about 19-23 nucleotides in length), which could regulate numerous human genes and play key roles in a variety of diseases. MiRNAs are dysregulated in lung cancer and participate in tumor initiation, development and drug resistance. Recent studies showed a new therapeutic strategy for cancer therapy based on miRNAs. In this review, we briefly summarize one classic pathway of miRNAs in lung cancer, and discuss a new miRNA-based therapeutic strategy to manage lung cancer.

Keywords: miRNA, lung cancer, non-small cell lung cancer, adenocarcinoma, resistance, therapeutic strategy.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 23
ISSUE: 39
Year: 2017
Page: [6011 - 6018]
Pages: 8
DOI: 10.2174/1381612823666170725141954
Price: $58

Article Metrics

PDF: 16
HTML: 2